Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients
Background. Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of reproductive age, whose clinical characteristics are hyperandrogenism (HA), ovulatory dysfunction, and polycystic ovary, often accompanied by insulin resistance (IR) and metabolic abnormalities. Glucagon-li...
Main Authors: | Jingwen Gan, Jie Chen, Rui-lin Ma, Yan Deng, Xue-song Ding, Shi-yang Zhu, Ai-jun Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2023-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2023/4288004 |
Similar Items
-
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome
by: Rui-Lin Ma, et al.
Published: (2021-12-01) -
The efficacy of metformin and exenatide in Polycystic Ovary Syndrome (PCOS) patients
by: Kesavan, Sanggeeta, et al.
Published: (2023) -
Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats
by: Xin Tao, et al.
Published: (2019-09-01) -
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
by: Yan Hu, et al.
Published: (2023-11-01) -
Triple therapy for obese patients with type 2 diabetes: evaluating effectiveness of the metformin + exenatide + glibenclamide combination
by: M. B. Antsiferov, et al.
Published: (2015-12-01)